Application of contrast-enhanced transrectal ultrasound during follow-up after targeted cryoablation for treating localized prostate cancer

XIE Shaowei; DONG Baijun; WANG Yanqing; XIA Jianguo; LI Hongli; ZHANG Shijun; YANG Wenqi; XUE Wei; LI Fenghua

doi:10.19732/j.cnki.1008-617X.2018.05.006

您当前的位置：

首页 >

文章列表页 >

Application of contrast-enhanced transrectal ultrasound during follow-up after targeted cryoablation for treating localized prostate cancer

更新时间：2025-12-15

- Application of contrast-enhanced transrectal ultrasound during follow-up after targeted cryoablation for treating localized prostate cancer
- Vol. 27, Issue 5, Pages: 370-374(2018)
- 作者机构：
  
  1. 上海交通大学医学院附属仁济医院超声医学科,上海,200127
  2. 上海交通大学医学院附属仁济医院泌尿外科,上海,200127
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.1008-617X.2018.05.006
  CLC：
- Published Online：14 November 2018，
  
  Published：14 November 2018
- 稿件说明：
移动端阅览
谢少伟,董柏君,王艳青,等. 实时超声造影在局灶性前列腺癌靶向冷冻消融治疗后随访中的应用价值[J]. 肿瘤影像学, 2018, 27(5): 370-374 https://doi.

org/10.19732/j.cnki.1008-617X.2018.05.006
谢少伟,董柏君,王艳青,等. 实时超声造影在局灶性前列腺癌靶向冷冻消融治疗后随访中的应用价值[J]. 肿瘤影像学, 2018, 27(5): 370-374 https://doi. DOI： 10.19732/j.cnki.1008-617X.2018.05.006.

org/10.19732/j.cnki.1008-617X.2018.05.006 DOI：

摘要

目的：

探讨实时经直肠超声造影（contrast-enhanced transrectal ultrasound，CETRUS）在局灶性前列腺癌靶向冷冻消融治疗后随访中的临床应用价值。

方法：

2014年6月2015年3月对15例病理证实为局灶性前列腺癌的患者行靶向冷冻消融术治疗，术后定期复查前列腺特异性抗原（prostate-specific antigen，PSA），所有患者于术前，术后第1天、6个月、1年及之后每年和生化复发（PSA高于术后最低值2 ng/mL）时行CETRUS检查。对比冷冻消融前后CETRUS图像变化，观察冷冻消融灶的CETRUS图像转归，评估消融效果。

结果：

术后随访中位时间为31.0个月，15例患者均存活，无新发转移病灶，73.3%（11/15）的患者随访无生化复发，CETRUS随访亦未发现异常。术后第1天CETRUS示冷冻消融灶内造影剂增强缺损区，或仅见个别造影剂微泡进入，边界不清，周围神经血管束增强不明显。术后6个月CETRUS示冷冻消融灶造影边界清晰，内未见造影剂微泡进入，可见包膜及周围神经血管束增强。术后1年CETRUS示冷冻消融范围稳定。出现生化复发的4例患者中，2例CETRUS检查发现冷冻消融灶内出现造影剂增强，予间歇性内分泌治疗，PSA下降；2例行CETRUS检查示冷冻消融灶内未出现造影剂进入，予主动监测，PSA稳定。

结论：

实时CETRUS是临床上局灶性前列腺癌靶向冷冻消融术后随访的有效影像学技术。

Abstract

Objective:

To evaluate the role of contrast-enhanced transrectal ultrasound (CETRUS) during follow-up after targeted cryoablation for treating localized prostate cancer.

Methods:

From Jun. 2014 to Mar. 2015

15 patients with pathologically confirmed localized prostate cancer underwent targeted cryoablation. The

y were subjected to prostate-specific antigen (PSA) analysis after therapy. All patients underwent CETRUS scanning before cryoablation and 1 d

6 months

1 year after cryoablation or biochemical recurrence (Phoenix definition). The preoperative and postoperative PSA and CETRUS results were compared

and the ablation effect was assessed.

Results:

The median follow-up period was 31.0 months

and all patients survived without local progression or metastasis. The biochemical disease-free survival was 73.3% (11/15). One day after cryoablation

CETRUS demonstrated no enhancement or only little contrast agent in ablation areas with unclear boundary; Six months after cryoablation

CETRUS demonstrated no enhancement in ablation areas with clear boundary; One year after cryoablation

CETRUS demonstrated satisfactoryablation extent in all patients. Four patients developed a biochemical recurrence

of which 2 patients revealed abnormal enhancement on CETRUS and received intermittent endocrine therapy and PSA levels decreased. Another two patients showed no enhancement on CETRUS

whose PSA levels were stable without any therapy.

Conclusion:

CETRUS is an effective imaging technology during follow-up after targeted cryoablation for treating localized prostate cancer.

关键词

Keywords

references

Views

1909

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Value of contrast-enhanced transrectal ultrasound in evaluating the response of prostate cancer to neoadjuvant hormonal therapy

Evaluation of prostate cancer across different treatment stages using ¹⁸F-FDG PET imaging

A comparative study of ⁶⁸Ga-TBM-001 PET/CT and ^99mTc-MDP bone scintigraphy in the diagnosis of bone metastases of prostate cancer

Advances in the application of ultrasound artificial intelligence in prostate cancer

A study on the quality of T2-weighted FatSat images of prostate and its diagnostic value based on deep learning reconstruction technology

Related Author

ZHAO Yunxin

ZHANG Bei

WANG Xiaolian

ZHOU Shihui

CAI Qiuqiong

KANG Huili

SUN Jian

YAO Guanglibr

Related Institution

Clinical Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences

Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Department of Nuclear Medicine, Affilitated Hospital of Southwest Medical University

Department of Nuclear Medicine, Chengdu Seventh People’s Hospital, Affilitated Cancer Hospital of Chengdu Medical College

Department of Radiology, Chengdu Seventh People’s Hospital, Affilitated Cancer Hospital of Chengdu Medical College

AI问答

⁰